Luca Palazzo

Dr. Luca Palazzo

Institute Experimental Endocrinology and Oncology, National Research Council of Italy, Naples, Italy
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2016 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
OLOrsolya Leidecker
Orsolya Leidecker
JBJuan José Bonfiglio
Juan José Bonfiglio
TCThomas Colby
Thomas Colby
QZQi Zhang
Qi Zhang
IAIlian Atanassov
Ilian Atanassov
IMIvan Matic
Ivan Matic
ADP-ribosylation is a post-translational protein modification that regulates numerous cellular pathways. An approach involving histone purification, partial filter-aided digestion and ETD mass spectrometry reveals that serine residues in histone proteins are ADP-ribosylated. ADP-ribosylation (ADPr) is a biologically and clinically important post-translational modification, but little is known about the amino acids it targets on cellular proteins. Here we present a proteomic approach for direct in vivo identification and quantification of ADPr sites on histones. We have identified 12 unique ADPr sites in human osteosarcoma cells and report serine ADPr as a new type of histone mark that responds to DNA damage.

26 February 2018 in eLife
Verified
Journal Article
Open access
LPLuca Palazzo
Luca Palazzo
OLOrsolya Leidecker
Orsolya Leidecker
EPEvgeniia Prokhorova
Evgeniia Prokhorova
HDHelen Dauben
Helen Dauben
IMIvan Matic
Ivan Matic
IAIvan Ahel
Ivan Ahel
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that synthesise ADP-ribosylation (ADPr), a reversible modification of proteins that regulates many different cellular processes. Several mammalian PARPs are known to regulate the DNA damage response, but it is not clear which amino acids in proteins are the primary ADPr targets. Previously, we reported that ARH3 reverses the newly discovered type of ADPr (ADPr on serine residues; Ser-ADPr) and developed tools to analyse this modification (Fontana et al., 2017). Here, we show that Ser-ADPr represents the major fraction of ADPr synthesised after DNA damage in mammalian cells and that globally Ser-ADPr is dependent on HPF1, PARP1 and ARH3. In the absence of HPF1, glutamate/aspartate becomes the main target residues for ADPr. Furthermore, we describe a method for site-specific validation of serine ADP-ribosylated substrates in cells. Our study establishes serine as the primary form of ADPr in DNA damage signalling.

26 June 2017 in eLife
Verified
Journal Article
Open access
PFPietro Fontana
Pietro Fontana
JBJuan José Bonfiglio
Juan José Bonfiglio
LPLuca Palazzo
Luca Palazzo
EBEdward Bartlett
Edward Bartlett
IMIvan Matic
Ivan Matic
IAIvan Ahel
Ivan Ahel
ADP-ribosylation (ADPr) is a posttranslational modification (PTM) of proteins that controls many cellular processes, including DNA repair, transcription, chromatin regulation and mitosis. A number of proteins catalyse the transfer and hydrolysis of ADPr, and also specify how and when the modification is conjugated to the targets. We recently discovered a new form of ADPr that is attached to serine residues in target proteins (Ser-ADPr) and showed that this PTM is specifically made by PARP1/HPF1 and PARP2/HPF1 complexes. In this work, we found by quantitative proteomics that histone Ser-ADPr is reversible in cells during response to DNA damage. By screening for the hydrolase that is responsible for the reversal of Ser-ADPr, we identified ARH3/ADPRHL2 as capable of efficiently and specifically removing Ser-ADPr of histones and other proteins. We further showed that Ser-ADPr is a major PTM in cells after DNA damage and that this signalling is dependent on ARH3.

6 February 2020 in Genes & Development
Verified
Journal Article
Open access
PDF file
JRJohannes Gregor Matthias Rack
Johannes Gregor Matthias Rack
LPLuca Palazzo
Luca Palazzo
IAIvan Ahel
Ivan Ahel
ADP-ribosylation is an intricate and versatile posttranslational modification involved in the regulation of a vast variety of cellular processes in all kingdoms of life. Its complexity derives from the varied range of different chemical linkages, including to several amino acid side chains as well as nucleic acids termini and bases, it can adopt. In this review, we provide an overview of the different families of (ADP-ribosyl)hydrolases. We discuss their molecular functions, physiological roles, and influence on human health and disease. Together, the accumulated data support the increasingly compelling view that (ADP-ribosyl)hydrolases are a vital element within ADP-ribosyl signaling pathways and they hold the potential for novel therapeutic approaches as well as a deeper understanding of ADP-ribosylation as a whole.

26 April 2017 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
LPLuca Palazzo
Luca Palazzo
AMAndreja Mikoč
Andreja Mikoč
IAIvan Ahel
Ivan Ahel

22 May 2015 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
LPLuca Palazzo
Luca Palazzo
BTBenjamin Thomas
Benjamin Thomas
AJAnn-Sofie Jemth
Ann-Sofie Jemth
TCThomas Colby
Thomas Colby
OLOrsolya Leidecker
Orsolya Leidecker
IAIvan Ahel
Ivan Ahel
ADP-ribosylation is a post-translational modification (PTM) of proteins found in organisms from all kingdoms of life which regulates many important biological functions including DNA repair, chromatin structure, unfolded protein response and apoptosis. Several cellular enzymes, such as macrodomain containing proteins PARG [poly(ADP-ribose) glycohydrolase] and TARG1 [terminal ADP-ribose (ADPr) protein glycohydrolase], reverse protein ADP-ribosylation. In the present study, we show that human Nudix (nucleoside diphosphate-linked moiety X)-type motif 16 (hNUDT16) represents a new enzyme class that can process protein ADP-ribosylation in vitro, converting it into ribose-5′-phosphate (R5P) tags covalently attached to the modified proteins. Furthermore, our data show that hNUDT16 enzymatic activity can be used to trim ADP-ribosylation on proteins in order to facilitate analysis of ADP-ribosylation sites on proteins by MS.